Volume 8, Issue 1 (Special Issue 2018)                   Clin Exc 2018, 8(1): 7-8 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

fallah S, Sobouti B. Meningococcal Vaccine. Clin Exc . 2018; 8 (1) :7-8
URL: http://ce.mazums.ac.ir/article-1-390-en.html
Iran university of medical sciences
Abstract:   (4730 Views)
Neisseria meningitidis has 13 clinically significant serogroups, classified according to the antigenic structure of their polysaccharide capsule. Six serogroups, A, B, C, Y, W-135, and X, are responsible for virtually all cases of the disease in humans.
Quadrivalent (Serogroups A, C, W-135, and Y)
There are currently three vaccines available in the US to prevent meningococcal disease, all quadrivalent in nature, targeting serogroups A, C, W-135, and Y:
Two conjugate vaccines (MCV-4), Menactra and Menveo, and One polysaccharide vaccine (MPSV-4), Menomune, produced by Sanofi Pasteur.
Bivalent (Serogroups C and Y): On 2012, the FDA approved a new combination vaccine against two types of meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, will prevent disease caused byNeisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. This is the first meningococcal vaccine that can be given to infants as young as six weeks old.
Serogroup A: A vaccine called MenAfriVac has been developed through a program called the Meningitis Vaccine Project and has the potential to prevent outbreaks of group A meningitis.
Serogroup B: Vaccines against serotype B meningococcal disease have proved difficult to produce, and require a different approach from vaccines against other serotypes.
Serogroup X: The occurrence of serogroup X has been reported in North America, Europe, Australia, and West Africa. Current meningoccocal meningitis vaccines are not known to protect against serogroup X N. meningitidis disease.
Side effects of the vaccine include: Common side effects include pain and redness around the site of injection (up to 50% of recipients). A small percentage of people develop a mild fever. As with any medication, a small proportion of people develop a severe allergic reaction. The highest risk was when individuals received a dose of Soliris within 2 weeks after being vaccinated with Bexsero.
Full-Text [PDF 332 kb]   (182 Downloads)    
Type of Study: Review | Subject: پزشکي قانوني
Received: 2018/12/8 | Accepted: 2018/12/8 | Published: 2018/12/8

Add your comments about this article : Your username or Email:

Send email to the article author

© 2019 All Rights Reserved | Clinical Excellence

Designed & Developed by : Yektaweb